Home> #BIGDATAFORBLOODCANCER campaign for patients/general audience: september 2021 - July 2022> Big data to improve the care for people with Myeloma

Big data to improve the care for people with Myeloma

August 24, 2021 10:00 - x 00, 0 - 00:00

#bigdataforbloodcancer, Myeloma

The HARMONY Alliance aims to improve the care for people with Myeloma. We have created a unique Big Data Platform with > 90.000 anonymized European patient records. Our partnership with more than 100 organizations will accelerate blood cancer research.

HARMONY Big Data Analytic tools are used to enable doctors to rapidly select the most promising treatment strategy for an individual patient. In addition, we develop Core Outcome Sets for blood cancers and organize activities for various audience groups in the blood cancer field. The active involvement of patient organizations ensures that our work is well-aligned with the needs of patients with leukemia.

Patients involved

Among HARMONY’s partners are 9 European patient umbrella organizations, the HARMONY Patient Cluster, including Leukanet, Acute Leukemia Advocates Network (ALAN), CCI Europe/Childhood Cancer International, CLL Advocates Network (CLLAN), CML Advocates Network, Lymphoma Coalition, International MDS Alliance, Myeloma Patients Europe (MPE) and MPN Advocates Network. Our patient advocates and their patient communities are involved in defining Core Outcomes Sets, designing Research Projects and interacting with patients and their families.

Our activities in Myeloma

Our Focus

MM: Multiple Myeloma >
Other Monoclonal Gammopathies - to follow

Our Key Research Questions

Which factors predict therapy resistance? Why do some patients die despite a successful initial treatment?
What is the optimal combination of drugs for various subgroups of patients? Do less intensive treatments suffice for certain subgroups? Which subgroups benefit most from expensive drugs? Many novel MM drugs are extremely expensive and may cause adverse effects.
Which factors predict if and how MM progresses from a pre-malignant condition to malignant metastatic disease?
What can MM tell us about the existence of putative cancer stem cells?
Read more >

Our Research Projects

Click here to view the 1st MM Research Project and learn more about the challenge, envisioned impact and our experts involved >
Click here to view the 2nd MM Research Project >
Click here for all Research Projects >
More projects are expected to be published in the near future.

Our Delphi Projects

What are Core Outcome Sets and Delphi surveys and why do we need help from patients, clinicians, regulators and industry? Read more >
Click here to find more information (flyers/factsheet) and to view the MM Delphi Survey >

HARMONY Patient Organization Partner for Myeloma

Videos

#BigDataforBloodcancer: Ananda Plate, of Myeloma Patients Europe, explains the need and the role of patients HARMONY.

#BigDataforBloodcancer: Solène Clavreul, of Myeloma Patients Europe, explains what kind of research patients can develop within HARMONY.

#BigDataforBloodcancer: Mattia D'Agostino, of University of Turin, explains the new risk stratification model for Multiple Myeloma.

More?

Please make use of the search option on the top right of this page for more results on the topic of your interest.

Receive the latest news. Click here to subscribe!

Public-private partnership for Big Data in Hematology

HARMONY and HARMONY PLUS are funded through the Innovative Medicines Initiative (IMI), Europe's largest public-private initiative aiming to speed up the development of better and safer medicines for patients. Funding is received from the IMI 2 Joint Undertaking and is listed under grant agreement for HARMONY No. 116026 and grant agreement for HARMONY PLUS No. 945406. This Joint Undertaking receives support from the European Union’s Horizon 2020 Research and Innovation Programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA).